CompanyGraph
Oxford Nanopore Technologies plc
ONT · United Kingdom
Detects DNA and RNA base sequences by measuring electrical current disruptions as single molecules traverse engineered protein nanopores embedded in synthetic membranes.
Oxford Nanopore's detection mechanism depends on CsgG protein nanopores that lose structural functionality after a single sequencing run, so every run consumes a flow cell that cannot be reused and must be replaced with one carrying freshly expressed, quality-controlled protein. Because protein expression, folding verification, and quality control cannot be indefinitely accelerated, this biological production ceiling sets the hard upper bound on sequencing throughput regardless of how far software or device manufacturing scales. The flow cells carrying those proteins are temperature-sensitive and require uninterrupted cold-chain logistics from Oxford to customers globally, so Brexit restrictions on biological material movement, Chinese import controls on genomics technology, and cold-chain disruptions each degrade the same nanopores that the entire detection mechanism depends on, with no stockpiling buffer available to absorb the gap. Laboratories that have built real-time workflows around MinION portability face reconfiguration costs that make switching to alternative platforms difficult, which means the customer base depends on continuous flow cell supply through the same logistically fragile path that the biological production ceiling already constrains.
How does this company make money?
Hardware is sold as an initial device purchase, followed by recurring sales of consumable flow cells bought per sequencing run. High-throughput PromethION installations — larger laboratory instruments designed for greater sequencing volume — generate additional income through service contracts and software licensing.
What makes this company hard to replace?
Laboratory workflows built around real-time data streams cannot easily revert to batch-mode sequencing that requires hours for library preparation and cluster generation. MinION — the company's portable sequencing device — is integrated with existing laboratory information management systems in ways that require reconfiguration to switch to alternative sequencing platforms. Field deployment protocols for outbreak surveillance depend on MinION portability that desktop sequencers cannot replicate.
What limits this company?
Protein expression systems that produce functional CsgG nanopores cannot be indefinitely accelerated: each batch requires individual expression, folding verification, and quality control before incorporation into flow cells. This biological production ceiling — not device manufacturing or software — sets the hard upper bound on how many sequencing runs can be supported at any point in time.
What does this company depend on?
The mechanism depends on engineered CsgG protein nanopores licensed from the University of Oxford, specialized semiconductor fabrication for the ASIC chips that detect current changes, cold-chain logistics for shipping temperature-sensitive flow cells, consumable manufacturing at Oxford Science Park, and regulatory clearances for in vitro diagnostic applications — a category covering tests performed on biological samples outside the body — in target markets.
Who depends on this company?
Academic genomics laboratories would lose real-time sequencing capability for fieldwork and rapid pathogen identification if supply were interrupted. Clinical laboratories performing infectious disease surveillance would revert to slower sequencing methods that cannot provide same-day results. Agricultural genomics programs would lose portable DNA analysis for on-site crop and livestock genetic screening.
How does this company scale?
Software algorithms and device manufacturing replicate across units at low incremental cost, but each flow cell requires fresh biological nanopore proteins that must be individually produced and quality-controlled through protein expression systems that cannot be indefinitely accelerated, keeping biological production as the persistent bottleneck regardless of how far other parts of the operation scale.
What external forces can significantly affect this company?
Brexit trade barriers affect the movement of biological materials between UK manufacturing and EU customers. Chinese restrictions on genomics technology imports limit access to major sequencing markets. Cold-chain shipping disruptions during global logistics crises degrade temperature-sensitive flow cells before they reach customers.
Where is this company structurally vulnerable?
The differentiator is a biological protein rather than a chemical reagent, so the flow cells that carry it are temperature-sensitive, degrade during storage, and require cold-chain logistics from the Oxford Science Park manufacturing site to customers globally. Any sustained disruption to cold-chain integrity, Brexit-related restrictions on movement of biological materials into EU markets, or Chinese import restrictions on genomics technology directly degrades the functional nanopores that the entire detection mechanism depends on, with no stockpiling buffer available to absorb the gap.